Streptomycin Sulfate
FDA-approved product (injectable, injection), marketed as Streptomycin Sulfate.
- Registered studies
- 32
- Lab records
- 63
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Chancroid
- Granuloma inguinale
- Infection
- Pneumonia
- Septicemic plague
- Tuberculosis
- Tularemia
- Urinary tract infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Antibiotics; Streptomycins
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01GA01; WHO ATC A07AA04; WHO ATC A07AA54
Repurposing investigation
Streptomycin Sulfate is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA74.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli71.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae75.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis87.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
32registered studies name this medicine, for any condition. See them below.
Experimental
- MRSA: measured active in 2 of 2 lab records
- E. coli: measured active in 4 of 4 lab records
- K. pneumoniae: measured active in 15 of 15 lab records
- M. tuberculosis: measured active in 41 of 42 lab records
Show the 63 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Streptomycin Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- FurazolidoneExisting use: Other antiinfectives and antiseptics91.4% AI-predicted activityagainst M. tuberculosisLab records exist49 registered studies
- TriflupromazineExisting use: Psychosis90.6% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- ValdecoxibExisting use: Dysmenorrhea, Osteoarthritis, Rheumatic disease and 1 more88.6% AI-predicted activityagainst M. tuberculosisLab records exist31 registered studies
- CelecoxibExisting use: Ankylosing spondylitis, Cancer, Colorectal neoplasm and 15 more87.6% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Dorzolamide HydrochlorideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma86.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- MethazolamideExisting use: Glaucoma, Open-angle glaucoma85.6% AI-predicted activityagainst M. tuberculosisLab records exist11 registered studies
- AcetazolamideExisting use: Altitude sickness, Angle-closure glaucoma, Congestive heart failure and 5 more85.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- Trifluoperazine HydrochlorideExisting use: Anxiety disorder, Mental or behavioural disorder, Psychosis and 1 more84.6% AI-predicted activityagainst M. tuberculosis1 registered study
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives84.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- NitrofurazoneExisting use: Eye infection, Leishmaniasis, Trypanosomiasis84.0% AI-predicted activityagainst M. tuberculosis8 registered studies
- BrinzolamideExisting use: Glaucoma, Ocular hypertension, Open-angle glaucoma83.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- ZonisamideExisting use: Epilepsy, Focal-onset seizure, Partial epilepsy and 1 more82.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Evaluation of Viral Replication by Tonate Virus (TONV) and Zika Virus (ZIKV), Within an ex Vivo Trophoblast and Placental Model
NCT05589012 · start 2023-11-01
Registered record
- Registry ID
- NCT05589012
- Conditions
- Zika Virus Infection
- Interventions
- Cell line and virus; Infection of human placental culture explants; Determination of viral load in tissues by qRT-PCR
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Withdrawn
- Start
- 2023-11-01
- Completion
- 2024-04-01
- Enrolment
- 0
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionZika Virus InfectionInterventionCell line and virus; Infection of human placental culture explants; Determination of viral load in tissues by qRT-PCRPhaseNot recordedRegistry statusWithdrawnComparison of Keloid Volume and Symptoms Reduction Between Intralesional Umbilical-Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide Injection as Keloid Therapy: A Randomised Controlled Trial
NCT05887804 · start 2021-10-01
Registered record
- Registry ID
- NCT05887804
- Conditions
- Keloid; Stem Cell
- Interventions
- umbilical cord-derived mesenchymal stem cells (UC-MSC); umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM); Triamcinolone Acetonide (TA)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2021-10-01
- Completion
- 2022-06-09
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKeloid; Stem CellInterventionumbilical cord-derived mesenchymal stem cells (UC-MSC); umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM); Triamcinolone Acetonide (TA)PhasePhase 4Registry statusCompletedThe Effect of Intralesian Injection of Umbilical Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide on Type 1:3 Collagen Ratio and Interleukin-10 Levels in Keloid: A Randomised Controlled Trial
NCT05939817 · start 2021-10-01
Registered record
- Registry ID
- NCT05939817
- Conditions
- Keloid; Stem Cell
- Interventions
- umbilical cord-derived mesenchymal stem cells (UC-MSC); umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM); Triamcinolone Acetonide (TA)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2021-10-01
- Completion
- 2022-06-09
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKeloid; Stem CellInterventionumbilical cord-derived mesenchymal stem cells (UC-MSC); umbilical cord-derived mesenchymal stem cells conditioned medium (UC-CM); Triamcinolone Acetonide (TA)PhasePhase 4Registry statusCompletedMucosal-Associated Invariant T Cells in Cases of Miscarriage
NCT04492098 · start 2021-06-01
Registered record
- Registry ID
- NCT04492098
- Conditions
- Miscarriage
- Interventions
- MAIT cells
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2021-06-01
- Completion
- 2022-12-01
- Enrolment
- 50
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMiscarriageInterventionMAIT cellsPhaseNot recordedRegistry statusCompletedSafety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants
NCT05386810 · start 2020-11-05
Registered record
- Registry ID
- NCT05386810
- Conditions
- Poliomyelitis
- Interventions
- Experimental vaccine; IPV control vaccine; single-person sIPV control vaccine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2020-11-05
- Completion
- 2023-07-20
- Enrolment
- 1,572
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPoliomyelitisInterventionExperimental vaccine; IPV control vaccine; single-person sIPV control vaccinePhasePhase 3Registry statusCompletedCiprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin for Bubonic Plague
NCT04110340 · start 2020-02-15
Registered record
- Registry ID
- NCT04110340
- Conditions
- Plague, Bubonic; Plague, Pneumonic
- Interventions
- Ciprofloxacin; Streptomycin; Gentamicin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2020-02-15
- Completion
- 2025-02-05
- Enrolment
- 222
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPlague, Bubonic; Plague, PneumonicInterventionCiprofloxacin; Streptomycin; GentamicinPhasePhase 3Registry statusCompletedInduced Pluripotent Stem Cells for the Development of Novel Drug Therapies for Inborn Errors of Metabolism (iPSC-IEM)
NCT04097275 · start 2019-08-01
Registered record
- Registry ID
- NCT04097275
- Conditions
- Inborn Errors of Metabolism
- Interventions
- Skin biopsy; Withdraw of blood
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2019-08-01
- Completion
- 2024-08-01
- Enrolment
- 1,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInborn Errors of MetabolismInterventionSkin biopsy; Withdraw of bloodPhaseNot recordedRegistry statusUnknownPopulation Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis
NCT03625739 · start 2018-07-01
Registered record
- Registry ID
- NCT03625739
- Conditions
- Tuberculosis
- Interventions
- anti-tuberculosis drug
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Recruiting
- Start
- 2018-07-01
- Completion
- 2026-12-31
- Enrolment
- 800
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTuberculosisInterventionanti-tuberculosis drugPhaseNot recordedRegistry statusRecruitingThe Individualized M(X) Drug-resistant TB Treatment Strategy Study
NCT03237182 · start 2017-06-14
Registered record
- Registry ID
- NCT03237182
- Conditions
- Tuberculosis, Multidrug-Resistant
- Interventions
- Individualized TB treatment with multiple drugs; Standardized TB treatment with multiple drugs
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Terminated
- Start
- 2017-06-14
- Completion
- 2022-12-19
- Enrolment
- 205
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTuberculosis, Multidrug-ResistantInterventionIndividualized TB treatment with multiple drugs; Standardized TB treatment with multiple drugsPhasePhase 4Registry statusTerminatedA Novel Surgical Method in the Treatment of Unstable Vitiligo
NCT03013049 · start 2016-01
Registered record
- Registry ID
- NCT03013049
- Conditions
- Vitiligo
- Interventions
- Non cultured epidermal cell suspension; Non cultured dermal cell suspension
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2016-01
- Completion
- 2017-06
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVitiligoInterventionNon cultured epidermal cell suspension; Non cultured dermal cell suspensionPhaseNot applicableRegistry statusUnknownAn Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
NCT02365623 · start 2015-02-18
Registered record
- Registry ID
- NCT02365623
- Conditions
- Tuberculosis, Multidrug-Resistant
- Interventions
- TMC207 (bedaquiline); Background Regimen (BR)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2015-02-18
- Completion
- 2018-11-08
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTuberculosis, Multidrug-ResistantInterventionTMC207 (bedaquiline); Background Regimen (BR)PhasePhase 2Registry statusCompletedEffect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .
NCT02387749 · start 2014-05
Registered record
- Registry ID
- NCT02387749
- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- mesenchymal stem cells
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2014-05
- Completion
- 2016-12
- Enrolment
- 10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetic Peripheral NeuropathyInterventionmesenchymal stem cellsPhaseNot applicableRegistry statusCompletedFGF19 and the Expression of IRS-1 and GLUT-1 in Gestational Diabetes Mellitus
NCT03816605 · start 2014-04
Registered record
- Registry ID
- NCT03816605
- Conditions
- Gestational Diabetes Mellitus
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2014-04
- Completion
- 2016-04
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGestational Diabetes MellitusInterventionNot recordedPhaseNot recordedRegistry statusCompletedPatients Response to Early Switch To Oral:Osteomyelitis Study
NCT02099240 · start 2014-03-06
Registered record
- Registry ID
- NCT02099240
- Conditions
- Osteomyelitis
- Interventions
- oral antibiotics; intravenous antibiotics
- Study type
- INTERVENTIONAL
- Phase
- Early phase 1
- Registry status
- Terminated
- Start
- 2014-03-06
- Completion
- 2018-11-07
- Enrolment
- 11
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionOsteomyelitisInterventionoral antibiotics; intravenous antibioticsPhaseEarly phase 1Registry statusTerminatedAllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery
NCT02065245 · start 2014-03-03
Registered record
- Registry ID
- NCT02065245
- Conditions
- Frailty
- Interventions
- Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs); Placebo; Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2014-03-03
- Completion
- 2020-10-02
- Enrolment
- 65
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFrailtyInterventionAllogeneic Human Mesenchymal Stem Cells (allo-hMSCs); Placebo; Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)PhasePhase 1 / Phase 2Registry statusCompleted